BIT Capital’s Dianthus Therapeutics DNTH Stock Holding History

BIT Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01M	Sell	12,000 -3,000	-20%	-$174K	0.05%	61
2025 Q4	$618K	Buy	+15,000	New	+$582K	0.02%	86
2022 Q4	–	Sell	-10,733	Closed	-$230K	–	150
2022 Q3	$230K	Buy	10,733 +5,952	+124%	+$163K	0.04%	119
2022 Q2	$95.6K	Buy	4,781 +2,187	+84%	+$54.1K	0.01%	99
2022 Q1	$140K	Buy	+2,594	New	+$142K	0.01%	98

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIT Capital's DNTH Position: Q1 2026 in Review

BIT Capital reduced its Dianthus Therapeutics (DNTH) stake by 20% in Q1 2026, selling an estimated $174K and leaving 12,000 shares worth $1.01M. The position accounts for 0.05% of the portfolio, ranked #61.

BIT Capital first reported a position in DNTH in Q1 2022 and has held it in 5 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

BIT Capital held 12,000 shares of Dianthus Therapeutics worth $1.01M as of Q1 2026.
BIT Capital sold 3,000 Dianthus Therapeutics shares in Q1 2026, an estimated $174K.
Dianthus Therapeutics made up 0.05% of BIT Capital's portfolio in Q1 2026, its #61 holding.
BIT Capital first reported a position in Dianthus Therapeutics in Q1 2022 and has held it in 5 quarters since.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on BIT Capital's 13F filing for Q1 2026, filed 13 May 2026.